Lannett has struck a deal giving it exclusive US distribution rights for 10 years to a generic version of Advair Diskus being developed by China’s Respirent.
Lannett has struck a deal with Chinese respiratory specialist Respirent to gain exclusive US distribution rights to Respirent’s proposed generic version of GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol).
The deal runs for 10 years from the point at which Lannett starts distributing the generic in the US following...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
